The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension

被引:138
作者
Rich, S [1 ]
McLaughlin, VV [1 ]
机构
[1] Rush Univ, Rush Med Coll, Dept Med, Cardiol Sect, Chicago, IL 60612 USA
关键词
D O I
10.1016/S0735-1097(99)00320-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES This study evaluated the response to prostacyclin dose reduction in patients with primary pulmonary hypertension (PPH) who developed high cardiac outputs. BACKGROUND Patients on prostacyclin require chronic upward dose titration to overcome tolerance to the medication. No upper limit of effective dose has been described. METHODS We studied 12 patients with PPH treated with chronic prostacyclin therapy who presented in high cardiac output states. Each patient underwent prostacyclin dose reduction under hemodynamic guidance targeted to reduce the cardiac index to less than or equal to 4 liter/min/M-2, unless rebound pulmonary hypertension occurred. Following dose reduction, patients were observed for changes in the effectiveness of the prostacyclin. RESULTS Patients were treated for 39 +/- 20 months, resulting in a 71% reduction in pulmonary vascular resistance compared to baseline. At the time of their most recent evaluation their cardiac outputs were increased to 10.1 +/- 2.3 liter/min. The patients underwent a 39% dose reduction (range 12% to 78%) resulting in a change of mean PAP from 45 to 46 mm Hg (p = NS), cardiac index from 7.4 +/- 1.4 to 4 +/- 0.74 liter/min/M-2 (p = 0.01), and pulmonary vascular resistance from 3.7 +/- 1.7 to 4.7 +/- 1.5 units (p < 0.001). In no instance did rebound pulmonary hypertension occur. However, the patients all retained their clinical benefit without a return of tolerance. CONCLUSIONS Excessive prostacyclin in PPH can lead to a high cardiac output state, suggesting it has important positive inotropic effects. In this circumstance, reducing the dose can allow the cardiac output to return to normal without worsening the clinical state. (J Am Coll Cardiol 1999;34:1184-7) (C) 1999 by the American College of Cardiology.
引用
收藏
页码:1184 / 1187
页数:4
相关论文
共 16 条
[1]   A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].
Barst, RJ ;
Rubin, LJ ;
Long, WA ;
McGoon, MD ;
Rich, S ;
Badesch, DB ;
Groves, BM ;
Tapson, VF ;
Bourge, RC ;
Brundage, BH ;
Koerner, SK ;
Langleben, D ;
Keller, CA ;
Murali, S ;
Uretsky, BF ;
Clayton, LM ;
Jobsis, MM ;
Blackburn, SD ;
Shortino, D ;
Crow, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301
[2]   SURVIVAL IN PRIMARY PULMONARY-HYPERTENSION WITH LONG-TERM CONTINUOUS INTRAVENOUS PROSTACYCLIN [J].
BARST, RJ ;
RUBIN, LJ ;
MCGOON, MD ;
CALDWELL, EJ ;
LONG, WA ;
LEVY, PS .
ANNALS OF INTERNAL MEDICINE, 1994, 121 (06) :409-415
[3]  
Dunn M J, 1989, Arch Mal Coeur Vaiss, V82 Spec No 4, P27
[4]   POSITIVE INOTROPIC EFFECT OF A STABLE ANALOG OF PGI2 AND OF PGI2 ON ISOLATED GUINEA-PIG ATRIA - MECHANISM OF ACTION [J].
FASSINA, G ;
TESSARI, F ;
DORIGO, P .
PHARMACOLOGICAL RESEARCH COMMUNICATIONS, 1983, 15 (08) :735-749
[5]   Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension [J].
McLaughlin, VV ;
Genthner, DE ;
Panella, MM ;
Rich, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (05) :273-277
[6]  
METSKETEL T, 1981, ACTA PHYSL SCAND, V223, P481
[7]   PROSTACYCLIN IS A CIRCULATING HORMONE [J].
MONCADA, S ;
KORBUT, R ;
BUNTING, S ;
VANE, JR .
NATURE, 1978, 273 (5665) :767-768
[8]   Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure [J].
Montalescot, G ;
Drobinski, G ;
Meurin, P ;
Maclouf, J ;
Sotirov, I ;
Philippe, F ;
Choussat, R ;
Morin, E ;
Thomas, D .
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (06) :749-755
[9]  
Munzel T, 1996, Am J Cardiol, V77, p24C, DOI 10.1016/S0002-9149(96)00185-3
[10]   CONVERTING-ENZYME INHIBITION IMPROVES CONGESTION AND SURVIVAL IN HYPERTENSIVE RATS WITH HIGH-OUTPUT HEART-FAILURE [J].
NISHIMURA, H ;
OKA, T ;
UEYAMA, M ;
KUBOTA, J ;
KAWAMURA, K .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1994, 23 (01) :149-154